Completed PHASE2 INTERVENTIONAL 2-arm NCT00550797

Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma

A Multi-center, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of 14-day Inhaled TPI ASM8 in Subjects With Asthma

Sponsor: Syntara

Conditions Allergic Asthma

Interventions TPI ASM8 placebo

Updated 6 times since 2017 Last updated: Nov 18, 2013 Started: Jan 31, 2008 Primary completion: Jul 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Allergic Asthma and is currently completed. Syntara leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Mar 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Syntara
i3 Research

Data source: Syntara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom